A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02439450. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)
Study identification
- NCT ID
- NCT02439450
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Heat Biologics
- Industry
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Interventions
- Viagenpumatucel-L Biological
- Nivolumab Drug
- Pembrolizumab Drug
- Pemetrexed Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2015
- Primary completion
- May 2, 2021
- Completion
- Nov 3, 2022
- Last update posted
- Sep 20, 2023
2015 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| UC San Diego | La Jolla | California | 92093 | — |
| BRRH Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Memorial Cancer Institute | Pembroke Pines | Florida | 33028 | — |
| Horizon Oncology Research | Lafayette | Indiana | 47905 | — |
| Ashland-Bellefonte Cancer Center | Ashland | Kentucky | 41101 | — |
| Baptist Health Louisville | Louisville | Kentucky | 40207 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| New York Oncology Hematology | Albany | New York | 12206 | — |
| Winthrop Hospital | Mineola | New York | 11501 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02439450, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2023 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02439450 live on ClinicalTrials.gov.